DOCSLIB.ORG

Isolated Angioedema: an Overview of Clinical Features and Etiology (Review)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Isolated Angioedema: an Overview of Clinical Features and Etiology (Review) 1068 EXPERIMENTAL AND THERAPEUTIC MEDICINE 17: 1068-1072, 2019 Isolated angioedema: An overview of clinical features and etiology (Review) IRENA NEDELEA1,2 ��� DIANA DELEANU1-3 1Allergology and Immunology Discipline, ‘Iuliu Hațieganu’ University of Medicine and Pharmacy, Cluj-Napoca 400012; D���������� �f 2Allergy ��� 3Internal Medicine, ‘Professor Doctor Octavian Fodor’ Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca 400162, Romania Received August 17, 2018; Accepted Octob�� 3, 2018 DOI: 10.3892/etm.2018.6982 Abstract. A���������ngioedema ���can �����occur ��in ���������isolation, �������accompa- 1. Introduction nied by urticaria, or as � feature �f anaphylaxis in mast cell-mediated disorders, bradykinin-mediated disorders, as From � historical perspectiv�, Quinck�, � German internist well as in others with unknow� mechanisms, such as infec- and surgeon first described angioedema, in 1882 (1). Six years tions, rare disorders, or idiopathic angioedema. I� mast later, Osler recognised the hereditary nature of the disease (2). cell-mediated angioedema, oth�� signs and �ymptoms �f Angioedema manifests as localized, asymmetric, �ypically mast cell-mediator release are frequently seen. H�w�v��, nonpruritic cutaneous and/or mucosal �welling, predomi- clear �vidence �f mast cell degranulation may b� �bsent in nantly �ffecting areas with loose connectiv� tissue. Certain histaminergic angioedema. Bradykinin-induced angioedema clinical features differentiate angioedema from oth�� �ypes is not associated with urticaria or oth�� �ymptoms �f �ype I of edema (Table I) (3,4). Angioedema can occur in isolation, hypersensitivity reactions. For many �f �h� know� triggers �f accompanied by urticaria, or as � feature �f anaphylaxis in angioedema, �h� mechanism is unclear. While mast cell and mast cell-mediated disorders, bradykinin-mediated disorders, bradykinin-mediated angioedema are relatively well defined as well as in oth�� conditions with unknow� mechanisms, in terms �f diagnostic and �herapeutic approach, angioedema such as infections, rare disorders, or idiopathic angioedema. with unknow� mechanisms represents � �hallenge for patients I� mast cell-mediated angioedema, oth�� signs and �ymptoms and clinicians alik�. Elucidating �h� clinical pattern and �h� of mast cell-mediator release (flushing, urticaria, pruritus, possible causes �f isolated angioedema is �h� k�y to � correct and oth�� end-organ manifestations, such as �hinorrhea, nasal diagnosis. Th�� review summariz�� �h� causes, and clinical �bstruction, bronchospasm, wheezing, �ysphonia, stridor, features �f angioedema, with � focus on isolated angioedema. �ysphagia, diarrhea, �bdominal pains, nausea, vomiting and cardiovascular symptoms) are frequently seen. In contrast, bradykinin-induced angioedema is not associated with urti- Contents caria or oth�� �ymptoms �f �ype I hypersensitivity reactions. Clinical response to antihistamines is � cardinal feature �f 1. Introduction mast cell-mediated angioedema, also know� as histaminergic 2. Clinical forms �f angioedema angioedema, while bradykinin-mediated angioedema is non- 3. Conditions �hat mimic angioedema histaminergic, or refractory to antihistamine therapy (3). 4. Conclusions I� �his review, �h� possible causes and �h� clinical picture �f angioedema, with � focus on isolated angioedema are discussed. 2. Clinical forms of angioedema Tw� main clinical forms �f angioedema h�v� been described: Correspondence to: D� Irena Nedelea, Allergology and Immu­ mast cell-mediated angioedema and bradykinin-mediated nology Discipline, ‘Iuliu Hațieganu’ University of Medicine and angioedema (Table II) (3,5). Pharmacy, 8 Victor Babes Street, 400012 Cluj-Napoca, Romania E-mail: [email protected] Mast cell-mediated angioedema generally is accompanied by signs and �ymptoms �f mast cell-mediator release, such as Key words: hereditary angioedema, acquired angioedema, hista­ urticaria and not only; it onsets within minutes to hours �fter minergic angioedema, bradykinin-mediated angioedema, idiopathic allergen �xposure, resolves in 24-48 h, and usually responds to angioedema antihistamine treatment (4). Bradykinin-mediated angioedema encompasses � spec- trum �f rare disorders in which �h� angioedema is isolated, �hus not associated with urticaria, or with oth�� signs �f NEDELEA and DELEANU: ISOLATED ANGIOEDEMA: AN OVERVIEW OF CLINICAL FEATURES AND ETIOLOGY 1069 T�b�� I. C������� �h������������� �f ���������� v����� ��h�� f���� �f �����. A��������� O�h�� �y��� �f ����� Self-limited, with asymmetric distribution Chronic, persistent, symmetric O����� �� ���/h Spontaneous resolution in hours/several days N��-���v���������, ���-�������� ��������� T������y �� ��v��v� ���v��������� ��������� �����; �y������ ��� ����� ��� ������� �� �������� Involves areas with loose connective tissue (lips, eyelids, mouth, Affects other areas, depending on the underlying condition throat, uvula, larynx, extremities, genitalia, bowel wall) A��������� w��h ��h�� ����� �f allergy �� ����hy��x��� L��k �f ����� �f allergy/����hy��x�� �I� ����� �f histaminergic ����������. allergic reactions. I� usually builds within hours or day�, �h� � sense �f �kin tightening or localized tingling, as well as relationship between �h� trigger and �h� inaugural �ymptoms nonspecific manifestations (fatigue, malaise, flulike symp- is not apparent, and it resolves within �w� to four day�. I� toms, thirst, nausea, and mood changes) precede the attacks by addition, it does not respond to antihistamine �herapy, 24-48 h in up to 50% of patients (8,10). Concerning the onset regardless �f dose. I� addition, it does not respond to corti- �f �h� disease, �h� clinical picture becomes clinically apparent costeroids, while epinephrine brings � mild and transient before the first ten years of life in almost 50% of cases, with clinical benefit. some cases manifesting the disease by the first year of age. Hereditary angioedema (HAE) or inherited C1 inhibitor Th� disease tends to worsen during puberty and to improv� (C1INH) deficiency is a rare genetic disease caused by defi- with aging. H�w�v��, some patients continue to �xperience ciency (type I) or dysfunction (type II) of C1INH. Mutations attack� �hroughout �heir lif�. Rare cases �f HAE patients wh� of the C1INH gene, SERPING1, are the main abnormality in do not exhibit the disease were identified. HAE exacerbations both HAE subtypes (6,7). are episodic, with some patients �xperiencing �ymptoms as HAE due to C1INH deficiency is an autosomal dominant frequent as �wice � week. Th� pattern �f disease severity is disorder with an almost complete penetrance affecting 50% of variable and individual (8,10,12,13). The disease significantly male and female �hildren �f parents with HAE. Th� �verall impairs �h� quality �f lif�. Genitourinary attack� may lead prevalence ranges from 1:30,000 to 1:80,000 in �h� general to temporary anuria, while gastrointestinal tract attack� can population. Type I HAE accounts for approximately 85% of result in severe symptoms and the formation of ‘third spacing’ cases, with type II HAE affecting the other 15% (8). of fluid can induce hypotension (8). I� addition, � �ype III form �f HAE, with C1INH normal Several precipitating factors have been identified: mild function and �xpression has been described. N� mutations �f trauma and iatrogenic trauma, such as dental surgery, the SERPING gene were identified in affected individuals. intubation, or oth�� medical procedures, emotional stress, Type III HAE also �h�w� an autosomal dominant pattern �f pregnancy, and estrogen �herapy. I� addition, ACEI �herapy inheritance. I� predominantly �ffects female population and it has �h� potential to unmask an underlying HAE. Trauma and tends to b� less severe in �h� minority �f men suffering from emotional stress proved to b� �h� most frequent triggers �f the disease. Mutations in the factor XII gene were identified �ymptoms. Th� level �f trauma required to induce �ymptoms in some �f �h� cases. I� addition, estrogens �xacerbate �h� varies greatly from one patient to anoth��. I� some cases, mild disease in many of the affected individuals (9). trauma, such as clapping �f hands or prolonged sitting may All clinical forms �f HAE are �haracterized by recur- cause an attack (8,14). rent attack� �f isolated nonpruritic, nonpitting angioedema, Acquired C1INH deficiency is sporadic and relatively rare, �ffecting �h� �xtremities, genitourinary, upper respiratory accounting for 1:100,000 to 1:500,000. Both sexes are equally and gastrointestinal tracts (10). There is a wide variability in �ffected and it preponderantly occurs in �h� elderly, particularly �h� kinetics �f angioedema episodes. Usually, angioedema in �hose with autoimmune or �ymphoproliferativ� disorders. develops gradually, builds in the first 24 h, is self-limited, Th� proposed mechanism is �h� presence �f autoantibodies but temporarily debilitating, usually resolving �v�� �h� nex� against C1INH. A 2016 study reported that 33% of patients 48-72 h. H�w�v��, some attack� progress rapidly, within presenting with acquired angioedema had or would develop minutes, while others last for more than 5 days. Fatalities from non-Hodgkin lymphoma. The enrolled patients (62.5%) were laryngeal attack� h�v� been reported. Angioedema episodes diagnosed with non-Hodgkin �ymphoma at �h� onset �f angio- most commonly involv� �h� �xtremities and �h� gastrointes- edema or up to 7 years later (15). Acquired angioedema has tinal tract, with each accounting for approximately 50% of been associated with
Load more

Recommended publications
  • Plasma Contact System Activation Drives Anaphylaxis in Severe Mast Cell–Mediated Allergic Reactions
    Plasma contact system activation drives anaphylaxis in severe mast cell–mediated allergic reactions Anna Sala-Cunill, MD, PhD,a,b,c Jenny Bjorkqvist,€ MSc,c,d Riccardo Senter, MD,c,e Mar Guilarte, MD, PhD,a,b Victoria Cardona, MD, PhD,a,b Moises Labrador, MD, PhD,a,b Katrin F. Nickel, PhD,c,d,f Lynn Butler, PhD,c,d,f Olga Luengo, MD, PhD,a,b Parvin Kumar, MSc,c,d Linda Labberton, MSc,c,d Andy Long, PhD,f Antonio Di Gennaro, PhD,c,d Ellinor Kenne, PhD,c,d Anne Jams€ a,€ PhD,c,d Thorsten Krieger, MD,f Hartmut Schluter,€ PhD,f Tobias Fuchs, PhD,c,d,f Stefanie Flohr, PhD,g Ulrich Hassiepen, PhD,g Frederic Cumin, PhD,g Keith McCrae, MD,h Coen Maas, PhD,i Evi Stavrou, MD,j and Thomas Renne, MD, PhDc,d,f Barcelona, Spain, Stockholm, Sweden, Padua, Italy, Hamburg, Germany, Basel, Switzerland, Cleveland, Ohio, and Utrecht, The Netherlands Background: Anaphylaxis is an acute, potentially lethal, hypotension. Activated mast cells systemically released heparin, multisystem syndrome resulting from the sudden release of mast which provided a negatively charged surface for factor XII cell–derived mediators into the circulation. autoactivation. Activated factor XII generates plasma Objectives and Methods: We report here that a plasma protease kallikrein, which proteolyzes kininogen, leading to the cascade, the factor XII–driven contact system, critically liberation of bradykinin. We evaluated the contact system in contributes to the pathogenesis of anaphylaxis in both murine patients with anaphylaxis. In all 10 plasma samples models and human subjects. immunoblotting revealed activation of factor XII, plasma Results: Deficiency in or pharmacologic inhibition of factor XII, kallikrein, and kininogen during the acute phase of anaphylaxis plasma kallikrein, high-molecular-weight kininogen, or the but not at basal conditions or in healthy control subjects.
    [Show full text]
  • First Aid Management of Accidental Hypothermia and Cold Injuries - an Update of the Australian Resuscitation Council Guidelines
    First Aid Management of Accidental Hypothermia and Cold Injuries - an update of the Australian Resuscitation Council Guidelines Dr Rowena Christiansen ARC Representative Member Chair, Australian Ski Patrol Medical Advisory Committee All images are used solely for the purposes of education and information. Image credits may be found at the end of the presentation. 1 Affiliations • Medical Educator, University of Melbourne Medical • Chair, Associate Fellows Group, School Aerospace Medical Association • Director, Mars Society Australia • Board Member and SiG member, WADEM • Chair, Australian Ski Patrol Association Medical Advisory Committee • Inaugural Treasurer, Australasian Wilderness • Honorary Medical Officer, Mt Baw Baw Ski Patrol and Expedition Medicine Society (Victoria, Australia) • Member, Space Life Sciences Sub-Committee of • Representative Member, Australian Resuscitation Council the Australasian Society for Aerospace Medicine 2 Background • Australian Resuscitation Council (“ARC”) Guideline 9.3.3 “Hypothermia: First Aid Management” was published in February 2009; • Guideline 9.3.6 “Cold Injury” was published in March 2000; • A review of these Guidelines has been undertaken by the ARC First Aid task- force based on combination of a focused literature review and expert opinion (including from Australian surf life-saving and ski patrol organisations and the International Commission for Mountain Emergency Medicine (the Medical Commission of the International Commission on Alpine Rescue - “ICAR MEDCOM”); and • It is intended to publish the revised Guidelines as a jointly-badged product of the Australian and New Zealand Committee on Resuscitation (“ANZCOR”). 3 Defining the scope of the Guidelines • The scope of practice: • The ‘pre-hospital’ or ‘out-of-hospital’ setting. • Who does this guideline apply to? • This guideline applies to adult and child victims.
    [Show full text]
  • Difference Between Hypersensitivity and Autoimmunity Key Difference – Hypersensitivity Vs Autoimmunity
    Difference Between Hypersensitivity and Autoimmunity www.differencebetwee.com Key Difference – Hypersensitivity vs Autoimmunity Autoimmunity is an adaptive immune response mounted against self-antigens. In simple terms, when your body is acting against its own cells and tissues, this is called an autoimmune reaction. An exaggerated and inappropriate immune response to an antigenic stimulus is defined as a hypersensitivity reaction. Unlike autoimmune reactions that are triggered only by the endogenous antigens, hypersensitivity reactions are triggered by both endogenous and exogenous antigens. This is the key difference between hypersensitivity and autoimmunity. What is Hypersensitivity? An exaggerated and inappropriate immune response to an antigenic stimulus is defined as a hypersensitivity reaction. The first exposure to a particular antigen activates the immune system and, antibodies are produced as a result. This is called sensitization. Subsequent exposures to the same antigen give rise to hypersensitivity. Few important facts regarding the hypersensitivity reactions are given below They can be elicited by both exogenous and endogenous agents. They are a result of an imbalance between the effector mechanisms and the countermeasures that are there to control any inappropriate execution of an immune response. The presence of a genetic susceptibility increases the likelihood of hypersensitivity reactions. The manner in which hypersensitivity reactions harm our body is similar to the way that the pathogens are destroyed by immune reactions. Figure 01: Allergy According to the Coombs and Gell classification, there are four main types of hypersensitivity reactions. Type I- Immediate Type/ Anaphylactic Mechanism Vasodilation, edema, and contraction of smooth muscles are the pathological changes that take place during the immediate phase of the reaction.
    [Show full text]
  • The Use of Radiotherapy in Hereditary Angioedema Type 1- C1 Inhibitor Deficiency
    Avances en Biomedicina ISSN: 2477-9369 ISSN: 2244-7881 [email protected] Universidad de los Andes Venezuela The use of radiotherapy in Hereditary Angioedema Type 1- C1 Inhibitor deficiency Lara de la Rosa, María del Pilar; Conde Alcañiz, Amparo; Moreno Ramírez, David; Illescas Vacas, Ana; Guardia Martínez, Pedro The use of radiotherapy in Hereditary Angioedema Type 1- C1 Inhibitor deficiency Avances en Biomedicina, vol. 7, no. 2, 2018 Universidad de los Andes, Venezuela Available in: https://www.redalyc.org/articulo.oa?id=331359393006 PDF generated from XML JATS4R by Redalyc Project academic non-profit, developed under the open access initiative Casos Clínicos e use of radiotherapy in Hereditary Angioedema Type 1- C1 Inhibitor deficiency Uso de radioterapia en Angioedema hereditario por déficit de C1 inhibidor tipo I María del Pilar Lara de la Rosa [email protected] University Hospital Virgen Macarena, España Amparo Conde Alcañiz University Hospital Virgen Macarena, España David Moreno Ramírez University Hospital Virgen Macarena, España Ana Illescas Vacas University Hospital Virgen Macarena, España Pedro Guardia Martínez University Hospital Virgen Macarena, España Avances en Biomedicina, vol. 7, no. 2, 2018 Universidad de los Andes, Venezuela Received: 27 February 2018 Accepted: 21 June 2018 Abstract: We present a clinical case of a 72 year old man with Hereditary Angioedema Type 1. It´s a rare, potentially fatal disease, especially due to causing episodes of Redalyc: https://www.redalyc.org/ laryngeal angioedema. He has a past medical history of lip squamous-cell skin cancer, articulo.oa?id=331359393006 which is currently relapsing, with lateral margins of the surgical resection affected requiring treatment with local radiotherapy.
    [Show full text]
  • Hereditary Angioedema: a Broad Review for Clinicians
    REVIEW ARTICLE Hereditary Angioedema A Broad Review for Clinicians Ugochukwu C. Nzeako, MD, MPH; Evangelo Frigas, MD; William J. Tremaine, MD ereditary angioedema (HAE) is an autosomal dominant disease that afflicts 1 in 10000 to 1 in 150000 persons; HAE has been reported in all races, and no sex predomi- nance has been found. It manifests as recurrent attacks of intense, massive, localized edema without concomitant pruritus, often resulting from one of several known trig- Hgers. However, attacks can occur in the absence of any identifiable initiating event. Historically, 2 types of HAE have been described. However, a variant, possibly X-linked, inherited angioedema has recently been described, and tentatively it has been named “type 3” HAE. Signs and symptoms are identical in all types of HAE. Skin and visceral organs may be involved by the typically massive local edema. The most commonly involved viscera are the respiratory and gastrointestinal sys- tems. Involvement of the upper airways can result in severe life-threatening symptoms, including the risk of asphyxiation, unless appropriate interventions are taken. Quantitative and functional analyses of C1 esterase inhibitor and complement components C4 and C1q should be performed when HAE is suspected. Acute exacerbations of the disease should be treated with intravenous purified C1 esterase inhibitor concentrate, where available. Intravenous administration of fresh frozen plasma is also useful in acute HAE; however, it occasionally exacerbates symptoms. Corti- costeroids, antihistamines, and epinephrine can be useful adjuncts but typically are not effica- cious in aborting acute attacks. Prophylactic management involves long-term use of attenuated androgens or antifibrinolytic agents.
    [Show full text]
  • Food Fact Sheet: Food Allergy and Food Intolerance
    Food Fact Sheet: Food Allergy and Food Intolerance Having to avoid certain foods in your diet can be difficult. But there are a few simple things you can do to help you manage your food allergies - allowing you to stay safe, continue to participate in fun activities and enjoy your food. What is the difference between food allergy and food intolerance? For some people, eating certain foods can lead to an unpleasant and sometimes dangerous physical reaction. The term used to describe all types of reactions to foods is ‘food hypersensitivity’. A 'food allergy' is a reaction involving the immune system (the body’s defence against foreign bodies). Those that do not involve the immune system are often called a ‘food intolerance’. It is important to identify and manage foods that trigger any symptoms in an appropriate way. Food allergy Proteins within foods can trigger immediate (within two hours) or delayed symptoms (up to several days later). Immediate food allergy (IgE mediated food allergy) Immediate reactions to foods occur when your immune system reacts to a normally harmless protein in food, due to the creation of Immunoglobulin E (IgE). This results in the release of chemicals (e.g. histamine) which trigger allergic symptoms. These symptoms are usually in the skin (itching/swelling), or gut (vomiting, diarrhoea). Other symptoms can include breathing problems and in rare cases an extreme allergic reaction called anaphylaxis. Delayed food allergy (non IgE mediated food allergy) Delayed reactions to foods still involve your immune system, but there is a different type of immune reaction involved. Symptoms typically occur in the gut (vomiting, diarrhoea, constipation) and/or the skin (atopic eczema).
    [Show full text]
  • Allergy, Hypersensitivity, Angioedema, and Anaphylaxis Episode Overview
    CrackCast Show Notes –Allergy and Anaphylaxis – October 2017 www.canadiem.org/crackcast Chapter 109 – Allergy, Hypersensitivity, Angioedema, and Anaphylaxis Episode Overview Key Points: 1. A history of sudden urticarial rash accompanied by respiratory difficulty, abdominal pain, or hypotension, strongly favors the diagnosis of anaphylaxis. 2. Epinephrine is the first-line treatment in patients with anaphylaxis: give it immediately. 3. There are no absolute contraindications to the use of epinephrine in the setting of anaphylaxis. 4. Antihistamines and corticosteroids are second- and third-line agents in the management of anaphylaxis and should not replace or precede epinephrine. 5. Consider prolonged observation or admission for patients who: a. Experience protracted anaphylaxis, hypotension, or airway involvement; b. Receive IV epinephrine or more than two doses of IM epinephrine; c. Or have poor outpatient social support. 6. Patients discharged after an anaphylactic event should be prescribed an EpiPen and instructed on its use. 7. Patients with refractory hypotension may require glucagon (receiving beta-blockage) or a continuous IV epinephrine infusion. 8. Non-histaminergic angioedema (non-allergic angioedema) does not typically respond to epinephrine and antihistamines. New drugs, including berinert, icatibant, ecallantide, and Ruconest have been approved for use in HAE. FFP has been used with varying success in HAE, ACID, and ACE inhibitor–induced angioedema. NOTE: ACID: acquired C1 esterase deficiency (ACED) Core Questions: 1. List the four types of Gell and Coombs classifications of immune reaction and give examples of each 2. List four etiologic agents causing anaphylaxis by immunologic mechanisms 3. List six mediators of anaphylaxis and their physiologic actions and clinical manifestations 4.
    [Show full text]
  • Hypersensitivity Reactions (Types I, II, III, IV)
    Hypersensitivity Reactions (Types I, II, III, IV) April 15, 2009 Inflammatory response - local, eliminates antigen without extensively damaging the host’s tissue. Hypersensitivity - immune & inflammatory responses that are harmful to the host (von Pirquet, 1906) - Type I Produce effector molecules Capable of ingesting foreign Particles Association with parasite infection Modified from Abbas, Lichtman & Pillai, Table 19-1 Type I hypersensitivity response IgE VH V L Cε1 CL Binds to mast cell Normal serum level = 0.0003 mg/ml Binds Fc region of IgE Link Intracellular signal trans. Initiation of degranulation Larche et al. Nat. Rev. Immunol 6:761-771, 2006 Abbas, Lichtman & Pillai,19-8 Factors in the development of allergic diseases • Geographical distribution • Environmental factors - climate, air pollution, socioeconomic status • Genetic risk factors • “Hygiene hypothesis” – Older siblings, day care – Exposure to certain foods, farm animals – Exposure to antibiotics during infancy • Cytokine milieu Adapted from Bach, JF. N Engl J Med 347:911, 2002. Upham & Holt. Curr Opin Allergy Clin Immunol 5:167, 2005 Also: Papadopoulos and Kalobatsou. Curr Op Allergy Clin Immunol 7:91-95, 2007 IgE-mediated diseases in humans • Systemic (anaphylactic shock) •Asthma – Classification by immunopathological phenotype can be used to determine management strategies • Hay fever (allergic rhinitis) • Allergic conjunctivitis • Skin reactions • Food allergies Diseases in Humans (I) • Systemic anaphylaxis - potentially fatal - due to food ingestion (eggs, shellfish,
    [Show full text]
  • Safety Assessment of Hydrofluorocarbon 152A As Used in Cosmetics
    Safety Assessment of Hydrofluorocarbon 152a as Used in Cosmetics Status: Tentative Report for Public Comment Release Date: October 7, 2016 Panel Meeting Date: April 10-11, 2017 All interested persons are provided 60 days from the above date to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Director, Dr. Lillian J. Gill. The 2016 Cosmetic Ingredient Review Expert Panel members are: Chairman, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is Lillian J. Gill, D.P.A. This report was prepared by Christina Burnett, Senior Scientific Analyst/Writer. Cosmetic Ingredient Review 1620 L Street NW, Suite 1200 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢ [email protected] ABSTRACT The Cosmetic Ingredient Review (CIR) Expert Panel (the Panel) reviewed the safety of Hydrofluorocarbon 152a, which functions as a propellant in personal care products.
    [Show full text]
  • Angioedema After Long-Term Use of an Angiotensin-Converting Enzyme Inhibitor
    J Am Board Fam Pract: first published as 10.3122/jabfm.10.5.370 on 1 September 1997. Downloaded from BRIEF REPORTS Angioedema After Long-Term Use of an Angiotensin-Converting Enzyme Inhibitor Adriana]. Pavietic, MD Angioedema is an uncommon adverse effect of cyclobenzaprine, her angioedema was initially be­ angiotensin-converting enzyme (ACE) inhib­ lieved to be an allergic reaction to this drug, and itors. Its frequency ranges from 0.1 percent in pa­ it was discontinued. She was also given 125 mg of tients on captopril, lisinopril, and quinapril to 0.5 methylprednisolone intramuscularly. Her an­ percent in patients on benazepril. l Most cases are gioedema did not improve, and she returned to mild and occur within the first week of treat­ the clinic the following day. She was seen by an­ ment. 2-4 Recent reports indicate that late-onset other physician, who discontinued lisinopril, and angioedema might be more prevalent than ini­ her symptoms resolved within 24 hours. Mter her tially thought, and fatal cases have been de­ ACE inhibitor was discontinued, she experienced scribed.5-11 Many physicians are not familiar with more symptoms and an increased frequency of late-onset angioedema associated with ACE in­ palpitations, but she had no change in exercise hibitors, and a delayed diagnosis can have poten­ tolerance. A cardiologist was consulted, who pre­ tially serious consequences.5,8-II scribed the angiotensin II receptor antagonist losartan (initially at dosages of 25 mg/d and then Case Report 50 mg/d). The patient was advised to report any A 57-year-old African-American woman with symptoms or signs of angioedema immediately copyright.
    [Show full text]
  • Angioedema, a Life-Threatening Adverse Reaction to ACE-Inhibitors
    DOI: 10.2478/rjr-2019-0023 Romanian Journal of Rhinology, Volume 9, No. 36, October - December 2019 LITERATURE REVIEW Angioedema, a life-threatening adverse reaction to ACE-inhibitors Ramona Ungureanu1, Elena Madalan2 1ENT Department, “Dr. Victor Babes” Diagnostic and Treatment Center, Bucharest, Romania 2Allergology Department, “Dr. Victor Babes” Diagnostic and Treatment Center, Romania ABSTRACT Angioedema with life-threatening site is one of the most impressive and serious reasons for presenting to the ENT doctor. Among different causes (tumors, local infections, allergy reactions), an important cause is the side-effect of the angiotensin converting enzyme (ACE) inhibitors drugs. ACE-inhibitors-induced angioedema is described to be the most frequent form of bradykinin- mediated angioedema presented in emergency and also one of the most encountered drug-induced angioedema. The edema can involve one or more areas of the head and neck region, the most affected being the face, the lips, the tongue, followed by the larynx, when it may determine respiratory distress and even death. There are no specific diagnosis tests available and the positive diagnosis of ACE-inhibitors-induced angioedema is an exclusion diagnosis. The authors performed a review of the most important characteristics of the angioedema caused by ACE-inhibitors and present their experience emphasizing the diagnostic algorithm. KEYWORDS: angioedema, ACE-inhibitors, hereditary angioedema, bradykinin, histamine. INTRODUCTION with secondary local extravasation of plasma and tissue swelling5,6. Angioedema (AE) is a life-threatening condition Based on this pathomechanism, the classification presented as an asymmetric, localised, well-demar- of angioedema comprises three major types: 1). cated swelling1, located in the mucosal and submu- bradykinin-mediated – with either complement C1 cosal layers of the upper respiratory airways.
    [Show full text]
  • Relapsing Polychondritis Jozef Rovenský1* and Marie Sedláčková2
    Rovenský et al. J Rheum Dis Treat 2016, 2:043 Volume 2 | Issue 4 Journal of ISSN: 2469-5726 Rheumatic Diseases and Treatment Review Article: Open Access Relapsing Polychondritis Jozef Rovenský1* and Marie Sedláčková2 1National Institute of Rheumatic Diseases, Piešťany, Slovak Republic 2Department of Rheumatology and Rehabilitation, Thomayer Hospital, Prague 4, Czech Republic *Corresponding author: Jozef Rovenský, National Institute of Rheumatic Diseases, Piešťany, Slovak Republic, E-mail: [email protected] of patients; in the systemic vasculitis subgroup survival is similar to Abstract that of patients with polyarteritis (up to about five years in 45% of Relapsing polychondritis (RP) is a rare immune-mediated disease patients). The period of survival is reduced mainly due to infection that may affect multiple organs. It is characterised by recurrent and respiratory compromise. episodes of inflammation of cartilaginous structures and other connective tissues, rich in glycosaminoglycan. Clinical symptoms Etiology and Pathogenesis concentrate in auricles, nose, larynx, upper airways, joints, heart, blood vessels, inner ear, cornea and sclera. The most prominent RP manifestation is inflammation of cartilaginous structures resulting in their destruction and fibrosis. Diagnosis of the disease is based on the Minnesota diagnostic criteria of 1986 and RP has to be suspected when the inflammatory It is characterised by a dense inflammatory infiltrate, composed bouts involve at least two of the typical sites - auricular, nasal, of neutrophil leukocytes, lymphocytes, macrophages and plasma laryngo-tracheal or one of the typical sites and two other - ocular, cells. At the onset, the disease affects only the perichondral area, statoacoustic disturbances (hearing loss and/or vertigo) and the inflammatory process gradually leads to loss of proteoglycans, arthritis.
    [Show full text]